Search
Masitide, the nation's first GCG/GLP-1 dual-target drug for weight loss, made its debut with the issuance of the first prescription at Peking University People's Hospital. This groundbreaking medication is tailored for obese individuals with a BMI of 28 or higher and overweight individuals with a BMI of 24 or higher who suffer from comorbidities. By leveraging dual mechanisms of appetite suppression and metabolism acceleration, Masitide effectively sheds pounds and enhances metabolic indicators, including fatty liver and blood lipids. Phase III clinical trials demonstrated significant weight loss after 48 weeks of treatment, accompanied by a reduction in various health risks. For patient convenience, Masitide comes equipped with a pre-filled pen injection device, promoting long-term adherence to treatment.
-
C114 Communication Network -
Communication Home
